AVAlexis Viel

Alexis Viel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexis Viel has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Laurentie

    Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France

    6 shared publications
  • Jérôme Henri

    ANSES, French Agency for Food, Environmental and Occupational Health & Safety, Fougères Laboratory, Kinetics, Metabolism Modelling and Experiments Unit, 10 B rue Claude Bourgelat, 35306 Fougères, France

    4 shared publications
  • Aude A. Ferran

    Univ Toulouse, ENVT, INRAE, INTHERES, Toulouse, France

    3 shared publications
  • Jean-François Taillandier

    Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France

    3 shared publications
  • Marine Boulanger

    CiMMex unit, ANSES, Fougères Laboratory, France

    3 shared publications
  • Nicolas Grégoire

    Université de Poitiers, PHAR2, Inserm U1070, Poitiers, France - Laboratoire de Toxicologie et de Pharmacocinetique, CHU de Poitiers, Poitiers, France

    3 shared publications

Latest Publications

  • Open Access

    Unraveling Trimethoprim-Sulfonamide synergy against Escherichia coli through semi-mechanistic PK/PD modeling

    by Marine Boulanger, Sadate Tchalaou, Andrew Mead, Ludovic Pelligand, Ophélie Gourbeyre, Felipe Ramon-Portugal, Lucie Claustre, Marlène Z. Lacroix, Aude A. Ferran, Alexis Viel

    Trimethoprim/sulfonamide (TMP/S) is an antibiotic combination used in human and veterinary medicine for its synergistic effect. However, the recommended TMP/S dose ratio (1:5) in animals does not yield the targeted in vivo concentration ratio of 1:19, considered optimal for many human pathogens. Moreover, the diversity of TMP/S combinations used in veterinary medicine questions the relevance of a single universal ratio. Pharmacodynamic (PD) studies are therefore needed to characterize TMP/S time- and concentration-effect relationships. This study assessed three TMP/S combinations against three Escherichia coli strains using in vitro time-kill studies, with TMP and sulfonamides tested alone and in combination at multiple ratios. A semi-mechanistic pharmacokinetic (PK)/PD model was developed to quantify drug interactions and evaluated in a hollow-fiber infection model (HFIM) simulating poultry and equine PK for TMP/sulfadiazine (SDZ). Sulfonamides alone exhibited comparable maximal effects, lower than TMP alone. Bacterial regrowth was attributed to adaptive TMP resistance. Synergy was driven by TMP, reducing sulfonamide EC 50 values up to 92%. The most synergistic ratio was strain- and sulfonamide-dependent and differed from 1:19. HFIM results indicated that current TMP/SDZ dosing regimens are suboptimal in poultry but adequate in equine. Overall, these findings highlighted the importance of PK/PD-guided optimization for antibiotic combinations.

  • Open Access

    Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius

    by Andrew Mead, Alexis Viel, Marine Boulanger, Gudrun Overesch, Carl Ekstrand, Pierre‐Louis Toutain, Aude A. Ferran, Ludovic Pelligand

    Trimethoprim (TMP)‐sulfonamide combinations are widely used in veterinary medicine, yet the quantitative nature of their pharmacodynamic interaction remains incompletely characterised. This study investigated the interaction between TMP and sulfamethoxazole (SMX), sulfadiazine (SDZ) and sulfadimethoxine (SDMX) against two Staphylococcus pseudintermedius isolates using minimum inhibitory concentration (MIC) testing, time‐kill curve (TKC) experiments and semi‐mechanistic pharmacodynamic modelling incorporating a General Pharmacodynamic Interaction (GPDI) framework. TKC assays demonstrated enhanced antibacterial activity for TMP‐sulfonamide combinations compared with monotherapy, with the greatest bacterial killing observed at TMP:sulfonamide ratios of 1:4 and 1:19. The final GPDI model identified a predominantly unidirectional interaction in which sulfonamides increased TMP potency through concentration‐dependent reductions in TMP EC 50 of 86%–96% at saturating sulfonamide concentrations, corresponding to approximately 7‐ to 26‐fold maximal possible increases in TMP potency. Maximal synergy differed between sulfonamides, occurring at approximately 1:20 for TMP/SMX (~75% increase in killing), 1:40 for TMP/SDZ (~181%) and 1:5 for TMP/SDMX (~80%). Pharmacokinetic‐pharmacodynamic simulations of clinically relevant canine dosing regimens predicted transient bacterial suppression but not bacterial eradication. These findings demonstrate that TMP‐sulfonamide synergy is dynamic, concentration‐dependent and bacterial species‐specific, highlighting the importance of PK/PD‐informed optimisation of potentiated sulfonamide therapy in veterinary medicine.

  • Open Access

    Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves

    by Marine Boulanger, Béatrice B. Roques, Marlène Z. Lacroix, Lucie Claustre, Mathias Devreese, Siegrid De Baere, Alexis Viel, Aude A. Ferran

  • Open Access

    Pharmacodynamic interaction between trimethoprim and sulphonamides for A. pleuropneumoniae : synergistic ratios, optimal potentiation, and dynamic responses assessed via time-kill curves

    by Andrew Mead, Alexis Viel, Marine Boulanger, Gudrun Overesch, Pierre-Louis Toutain, Aude Ferran, Ludovic Pelligand

    Trimethoprim (TMP) and sulphonamides are widely used in combination to treat many conditions, including porcine respiratory infections caused by Actinobacillus pleuropneumoniae (APP), yet the pharmacodynamic basis of their synergy remains unclear. This study investigated the interactions between TMP and three sulphonamides (sulfamethoxazole, sulfadiazine, and sulfadimethoxine) against APP. Interactions were evaluated against three APP strains using MIC determination, static time-kill assays of individual drugs across five TMP: sulphonamide ratios (1:4, 1:19, 1:99, 1:499, 1:999), and semi-mechanistic pharmacodynamic modelling. Single-drug models showed greater TMP potency than sulphonamides (median EC50 0.018 µg mL−1 vs ∼3–10 µg mL−1). A General Pharmacodynamic Interaction model identified a unidirectional interaction in which TMP enhanced sulphonamide potency by reducing their EC50 at sub-MIC TMP concentrations (∼22-fold below the MIC), consistent with indirect antifolate action requiring folate depletion. Delayed sulphonamide effects and density-dependent growth limitation improved model performance. Maximal synergy, defined as the relative increase in bacterial killing rate, was 110–115% for all sulphonamides and occurred at a pharmacodynamic ratio of 1:250 (0.002 µg mL−1 TMP with 0.5 µg mL−1 sulphonamide). This represents a PD ratio and should not be confused with the classical 1:19 TMP: sulphonamide ratio reported for clinical effectiveness. Simulations using median porcine pharmacokinetics predicted rapid initial bacterial killing across intravenous and oral regimens despite pharmacokinetic ratio drift. However, sustained efficacy was regimen-dependent, with only the TMP-sulfadimethoxine combination achieving eradication, whereas others showed regrowth. These findings provide a mechanistic explanation of TMP–sulphonamide synergy against APP and highlight the value of semi-mechanistic PK/PD modelling for optimising veterinary combination therapy.


  • Usages de la colistine en médecine humaine et vétérinaire : exploration pharmacocinétique et problématique d'antibiorésistance

    by Alexis Viel

    La colistine est un vieil antibiotique, utilisé à la fois en médecine humaine et vétérinaire. Cependant, l'arsenal antibiotique étant de plus en plus limité, la colistine apparait comme un des derniers remparts dans la lutte contre les bactéries multi-résistantes chez l'Homme. Afin de préserver l'efficacité de la colistine, deux problématiques ont été abordées dans cette thèse : (i) les risques de sélection de résistance à la colistine en lien avec la découverte fin 2015 d'un gène porté par un plasmide (mcr-1). Ainsi, l'impact de l'usage de colistine par voie orale en production porcine a été évalué in vivo et une absence de sélection a été observée dans nos conditions expérimentales. De façon similaire, l'usage (minoritaire) de colistine en médecine humaine comme prophylaxie de décontamination digestive sélective (SDD) a été étudié chez des rats hébergeant un microbiote intestinal humain. Les résultats préliminaires ne montrent pas non plus d'effet de sélection. (ii) le développement d'un modèle pharmacocinétique basé sur la physiologie (PBPK) chez le porc pour l'usage par voie systémique de la colistine et de sa prodrogue, le colistine méthanesulfonate (CMS). Ce modèle a permis d'explorer la distribution tissulaire du CMS et de la colistine, notamment au niveau rénal où la toxicité est la plus fréquente. Comme application de ce modèle, l'estimation des temps d'attente avant abattage lors d'usage de CMS chez le porc a été effectué. Enfin, la capacité des modèles PBPK à réaliser des extrapolations intra et inter-espèces a été utilisé pour adapter ce modèle chez l'adulte et l'enfant, afin de pouvoir prédire les concentrations plasmatiques de colistine lors d'un traitement.

  • Semi-mechanistic PK/PD modeling of enrofloxacin against sensitive Pasteurella multocida : inter-strain variability and prediction of efficacy in pigs

    by Alexis Viel, Anthony Khaled, Mathias Devreese, Mireille Bruneau, Jérôme Henri

    Aims: This study aimed to investigate the inter-strain variability of enrofloxacin activity against Pasteurella multocida and to apply a pharmacokinetic/pharmacodynamic (PK/PD) modeling approach to predict the expected efficacy of enrofloxacin in pigs. Methods and results: In vitro and ex vivo time-kill curve (TKC) experiments were performed with enrofloxacin against nine susceptible P. multocida strains, and a semi-mechanistic PK/PD model was developed. Both bacterial net growth rates and enrofloxacin-mediated killing rates varied substantially among isolates; however, an overall strong bactericidal effect was consistently observed. At very high enrofloxacin concentrations, most strains exhibited a reduced killing rate (Eagle effect). A population PK model of enrofloxacin in pigs was also developed using published data. The integrated PK/PD model was then applied to simulate the expected efficacy in pigs of the United States and European dosing regimens (injectable formulations) of enrofloxacin against P. multocida, yielding comparable results across sensitive strains. Conclusions: Simulations from the PK/PD model suggest that the current CLSI breakpoints may be appropriate for defining enrofloxacin susceptibility in P. multocida, even from pigs treated with the European dosing regimen.

  • Open Access

    Pharmacokinetic modeling of sulfamethoxazole-trimethoprim and sulfadiazine-trimethoprim combinations in broilers

    by Marine Boulanger, Jean-François Taillandier, Jérôme Henri, Mathias Devreese, Siegrid De Baere, Aude A. Ferran, Alexis Viel


  • PBPK Model To Predict Marbofloxacin Distribution in Edible Tissues and Intestinal Exposure in Pigs

    by Alexis Viel, Anis Nouichi, Mélanie Le Van Suu, Jean-Guy Rolland, Pascal Sanders, Michel Laurentie, Jacqueline Manceau, Jérôme Henri

    Marbofloxacin (MAR) is a fluoroquinolone antibiotic used in food-producing animals in European Union, especially in pigs. In this study, MAR concentrations in plasma, comestible tissues, and intestinal segments were determined in pigs injected with MAR. Based on these data and the literature, a flow-limited PBPK model was developed to predict the tissue distribution of MAR and estimate the withdrawal period after label-use in Europe. A submodel describing the different segments of the intestinal lumen was also developed to assess the intestinal exposure of MAR for the commensal bacteria. During model calibration, only four parameters were estimated. Then, Monte Carlo simulations were performed to generate a virtual population of pigs. The simulation results were compared with the observations from an independent data set during the validation step. A global sensitivity analysis was also carried out to identify the most influential parameters. Overall, the PBPK model was able to adequately predict the MAR kinetics in plasma and edible tissues, as well as in small intestines. However, the simulated concentrations in the large intestine were mostly underestimated, highlighting the need for improvements in the field of PBPK modeling to assess the intestinal exposure of antimicrobials in food animals.


  • Presence and Depletion of Sulfadiazine, Trimethoprim, and Oxytetracycline into Feathers of Treated Broiler Chickens and Impact on Antibiotic-Resistant Bacteria

    by Estelle Dréano, Charlotte Valentin, Jean-François Taillandier, Angélique Travel, Christophe Soumet, Arnaud Bridier, Dominique Hurtaud-Pessel, Michel Laurentie, Alexis Viel, Sophie Mompelat

    The valorization of poultry byproducts, like feathers (processed to feather meal), in animal feed could contribute to the presence of veterinary drugs, including antibiotics. An animal study was carried out to study the fate of sulfadiazine, trimethoprim, and oxytetracycline in feathers, plasma, and droppings of broiler chickens. Cage and floor housing, different from current farm practices, were studied. Samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A longer presence of antibiotics was observed in feathers compared to plasma, with sulfadiazine being present the most. The internal presence (via blood) and the external presence (via droppings) of antibiotics in/on feathers were shown. Analysis of Escherichia coli populations, from droppings and feathers, highlighted that resistant bacteria could be transferred from droppings to feathers in floor-housed animals. The overall results suggest that feathers are a potential reservoir of antimicrobial residues and could contribute to the selection of antibiotic-resistant bacteria in the environment, animals, and humans.


  • Open Access

    Ionophore coccidiostats – disposition kinetics in laying hens and residues transfer to eggs

    by Abubakar Bello, Jérôme Henri, Alexis Viel, Jonathan Paul Mochel, Błażej Poźniak